Synergy Pharmaceuticals (NASDAQ:SGYP)‘s stock had its “hold” rating restated by stock analysts at Oppenheimer in a research report issued on Thursday.

Several other equities analysts have also recently weighed in on the company. HC Wainwright set a $7.00 price target on Synergy Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 5th. Zacks Investment Research cut Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 1st. BidaskClub cut Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 23rd. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Synergy Pharmaceuticals in a research report on Thursday, February 1st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. Synergy Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.08.

Synergy Pharmaceuticals stock opened at $1.91 on Thursday. The firm has a market capitalization of $488.39, a price-to-earnings ratio of -1.89 and a beta of 1.26. Synergy Pharmaceuticals has a 52-week low of $1.68 and a 52-week high of $4.86. The company has a debt-to-equity ratio of -21.05, a current ratio of 4.33 and a quick ratio of 3.88.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. The company had revenue of $9.40 million during the quarter, compared to analysts’ expectations of $7.12 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 1,333.76%. Synergy Pharmaceuticals’s revenue for the quarter was up 840.0% on a year-over-year basis. analysts anticipate that Synergy Pharmaceuticals will post -0.52 EPS for the current year.

A number of hedge funds have recently modified their holdings of SGYP. Advisor Group Inc. lifted its stake in Synergy Pharmaceuticals by 70.3% during the third quarter. Advisor Group Inc. now owns 43,650 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 18,025 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Synergy Pharmaceuticals by 71.3% during the third quarter. JPMorgan Chase & Co. now owns 3,405,377 shares of the biopharmaceutical company’s stock worth $8,820,000 after purchasing an additional 1,417,177 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Synergy Pharmaceuticals by 18.2% during the third quarter. Wells Fargo & Company MN now owns 219,676 shares of the biopharmaceutical company’s stock worth $638,000 after purchasing an additional 33,802 shares during the last quarter. Brown Advisory Inc. lifted its stake in Synergy Pharmaceuticals by 101.3% during the third quarter. Brown Advisory Inc. now owns 158,000 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 79,500 shares during the last quarter. Finally, Family Management Corp lifted its stake in Synergy Pharmaceuticals by 94.0% during the third quarter. Family Management Corp now owns 80,500 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 39,000 shares during the last quarter. 53.08% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Synergy Pharmaceuticals (SGYP) Earns “Hold” Rating from Oppenheimer” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/synergy-pharmaceuticals-sgyp-earns-hold-rating-from-oppenheimer/1959628.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Analyst Recommendations for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.